481 A CXCR4 partial agonist TFF2-MSA sensitized advanced gastric cancer to PD-1 blockade by systematically reducing PMN-MDSC accumulation, immunosuppression, and generation in bone marrow

BackgroundPolymorphonuclear myeloid-derived suppressor cell (PMN-MDSC) is pathologically activated immature neutrophil that exerts immunosuppressive functions. PMN-MDSC is short-lived and constantly replenished through bone marrow (BM) myelopoiesis. Within the BM, histidine decarboxylase (HDC) expre...

Full description

Saved in:
Bibliographic Details
Published inJournal for immunotherapy of cancer Vol. 11; no. Suppl 1; p. A540
Main Authors Qian, Jin, Ryeom, Sandra, Daugherty, Bruce L, Lederman, Seth, Wang, Timothy C
Format Journal Article
LanguageEnglish
Published London BMJ Publishing Group Ltd 01.11.2023
BMJ Publishing Group LTD
BMJ Publishing Group
Subjects
Online AccessGet full text

Cover

Loading…
Abstract BackgroundPolymorphonuclear myeloid-derived suppressor cell (PMN-MDSC) is pathologically activated immature neutrophil that exerts immunosuppressive functions. PMN-MDSC is short-lived and constantly replenished through bone marrow (BM) myelopoiesis. Within the BM, histidine decarboxylase (HDC) expressing immature neutrophil constitute a histaminergic niche that enforces hematopoietic stem cell quiescence and inhibits pathological myelopoiesis.1 Trefoil factor family 2 (TFF2), a partial agonist for CXCR4, inhibits CXCL12-dependent chemotaxis.2 Here we engineered a stabilized TFF2 peptide linked to mouse serum albumin (TFF2-MSA), and investigated its effect on PMN-MDSC and combination with PD1 inhibitor in advanced gastric cancer mouse models.MethodsA syngeneic gastric cancer cell line ACKP (Atp4b-Cre; Cdh1-/-; LSL-KrasG12D; Trp53-/-) was grafted subcutaneously into HDC-GFP transgenic mice to trace HDC-GFP+MDSCs. Once tumors reach 200 mm3, mice received TFF2-MSA or/and anti-PD-1 antibody. The CXCR4 antagonist AMD3100 served as comparison to TFF2-MSA. We further established a spontaneous lung metastasis model in which mice bearing ACKP tumors received surgical tumor resection and subsequent TFF2-MSA/anti-PD-1 treatments. In another orthotopic model, ACKP-luciferase cells were implanted to stomach submucosa, and the treatments started after 1 week. At 1 month, flow cytometry and single cell RNA sequencing (scRNA-seq) were performed to study treatment induced immune profile changes.ResultsEither TFF2-MSA or anti-PD-1 monotherapy showed little inhibition of subcutaneous ACKP tumor (15% and 25%, N=10, p>0.05), but their combination dramatically suppressed ACKP growth by 78% in a synergistic manner (p<0.0001). In the lung metastasis model, the combination completely abrogated metastasis in 80% mice (N=10, p<0.0001) and prolonged mice survival (p<0.0001), in contrast to minimal effect of either monotherapy (p>0.05). In the orthotopic model, although either monotherapy only slightly delayed tumor growth, their combination successfully eradicated tumor in 80% mice (N=5, p<0.001). Mechanistically, TFF2-MSA systematically reduced HDC+ PMN-MDSCs in the TME, spleen and blood, and its combination with anti-PD-1 profoundly increased polyfunctional Tim-3-Lag-3-CD8+ T cells in the TME and TCF1+ T cells in the TDLN. Inside BM, TFF2-MSA decreased PMN-MDSC generation from its precursors (MPP3/CMP/GMP/GP) to a level similar to tumor-free mice, and restored hematopoietic stem cell quiescence via histamine feedback loop. Importantly, flow cytometry, scRNA-seq and functional analysis suggested TFF2-MSA treated PMN-MDSCs display a more mature profile with less immunosuppressive property. In contrast, AMD3100 plus anti-PD-1 failed to decrease tumor growth and TME MDSCs possibly due to destruction of BM hematopoietic homeostasis.ConclusionsTFF2-MSA systematically reduced PMN-MDSC, and its immunosuppression and generation in BM, thereby sensitizing advanced gastric cancer to PD-1 inhibitors.ReferencesChen X, Deng H, Churchill MJ, Luchsinger LL, Du X, Chu TH, Friedman RA, Middelhoff M, Ding H, Tailor YH, Wang ALE, Liu H, Niu Z, Wang H, Jiang Z, Renders S, Ho SH, Shah SV, Tishchenko P, Chang W, Swayne TC, Munteanu L, Califano A, Takahashi R, Nagar KK, Renz BW, Worthley DL, Westphalen CB, Hayakawa Y, Asfaha S, Borot F, Lin CS, Snoeck HW, Mukherjee S, Wang TC. Bone Marrow Myeloid Cells Regulate Myeloid-Biased Hematopoietic Stem Cells via a Histamine-Dependent Feedback Loop. Cell Stem Cell. 2017 Dec 7;21(6):747–760.e7.Dubeykovskaya Z, Dubeykovskiy A, Solal-Cohen J, Wang TC. Secreted trefoil factor 2 activates the CXCR4 receptor in epithelial and lymphocytic cancer cell lines. J Biol Chem. 2009 Feb 6;284(6):3650–62.Ethics ApprovalFor experiments in mouse models, all procedures for mice were approved by the Institutional Animal Care and Use Committee of Columbia University in accordance with institutional and NIH guidelines (protocol number AC-AABV0664).
AbstractList BackgroundPolymorphonuclear myeloid-derived suppressor cell (PMN-MDSC) is pathologically activated immature neutrophil that exerts immunosuppressive functions. PMN-MDSC is short-lived and constantly replenished through bone marrow (BM) myelopoiesis. Within the BM, histidine decarboxylase (HDC) expressing immature neutrophil constitute a histaminergic niche that enforces hematopoietic stem cell quiescence and inhibits pathological myelopoiesis.1 Trefoil factor family 2 (TFF2), a partial agonist for CXCR4, inhibits CXCL12-dependent chemotaxis.2 Here we engineered a stabilized TFF2 peptide linked to mouse serum albumin (TFF2-MSA), and investigated its effect on PMN-MDSC and combination with PD1 inhibitor in advanced gastric cancer mouse models.MethodsA syngeneic gastric cancer cell line ACKP (Atp4b-Cre; Cdh1-/-; LSL-KrasG12D; Trp53-/-) was grafted subcutaneously into HDC-GFP transgenic mice to trace HDC-GFP+MDSCs. Once tumors reach 200 mm3, mice received TFF2-MSA or/and anti-PD-1 antibody. The CXCR4 antagonist AMD3100 served as comparison to TFF2-MSA. We further established a spontaneous lung metastasis model in which mice bearing ACKP tumors received surgical tumor resection and subsequent TFF2-MSA/anti-PD-1 treatments. In another orthotopic model, ACKP-luciferase cells were implanted to stomach submucosa, and the treatments started after 1 week. At 1 month, flow cytometry and single cell RNA sequencing (scRNA-seq) were performed to study treatment induced immune profile changes.ResultsEither TFF2-MSA or anti-PD-1 monotherapy showed little inhibition of subcutaneous ACKP tumor (15% and 25%, N=10, p>0.05), but their combination dramatically suppressed ACKP growth by 78% in a synergistic manner (p<0.0001). In the lung metastasis model, the combination completely abrogated metastasis in 80% mice (N=10, p<0.0001) and prolonged mice survival (p<0.0001), in contrast to minimal effect of either monotherapy (p>0.05). In the orthotopic model, although either monotherapy only slightly delayed tumor growth, their combination successfully eradicated tumor in 80% mice (N=5, p<0.001). Mechanistically, TFF2-MSA systematically reduced HDC+ PMN-MDSCs in the TME, spleen and blood, and its combination with anti-PD-1 profoundly increased polyfunctional Tim-3-Lag-3-CD8+ T cells in the TME and TCF1+ T cells in the TDLN. Inside BM, TFF2-MSA decreased PMN-MDSC generation from its precursors (MPP3/CMP/GMP/GP) to a level similar to tumor-free mice, and restored hematopoietic stem cell quiescence via histamine feedback loop. Importantly, flow cytometry, scRNA-seq and functional analysis suggested TFF2-MSA treated PMN-MDSCs display a more mature profile with less immunosuppressive property. In contrast, AMD3100 plus anti-PD-1 failed to decrease tumor growth and TME MDSCs possibly due to destruction of BM hematopoietic homeostasis.ConclusionsTFF2-MSA systematically reduced PMN-MDSC, and its immunosuppression and generation in BM, thereby sensitizing advanced gastric cancer to PD-1 inhibitors.ReferencesChen X, Deng H, Churchill MJ, Luchsinger LL, Du X, Chu TH, Friedman RA, Middelhoff M, Ding H, Tailor YH, Wang ALE, Liu H, Niu Z, Wang H, Jiang Z, Renders S, Ho SH, Shah SV, Tishchenko P, Chang W, Swayne TC, Munteanu L, Califano A, Takahashi R, Nagar KK, Renz BW, Worthley DL, Westphalen CB, Hayakawa Y, Asfaha S, Borot F, Lin CS, Snoeck HW, Mukherjee S, Wang TC. Bone Marrow Myeloid Cells Regulate Myeloid-Biased Hematopoietic Stem Cells via a Histamine-Dependent Feedback Loop. Cell Stem Cell. 2017 Dec 7;21(6):747–760.e7.Dubeykovskaya Z, Dubeykovskiy A, Solal-Cohen J, Wang TC. Secreted trefoil factor 2 activates the CXCR4 receptor in epithelial and lymphocytic cancer cell lines. J Biol Chem. 2009 Feb 6;284(6):3650–62.Ethics ApprovalFor experiments in mouse models, all procedures for mice were approved by the Institutional Animal Care and Use Committee of Columbia University in accordance with institutional and NIH guidelines (protocol number AC-AABV0664).
Author Wang, Timothy C
Qian, Jin
Lederman, Seth
Daugherty, Bruce L
Ryeom, Sandra
Author_xml – sequence: 1
  givenname: Jin
  surname: Qian
  fullname: Qian, Jin
  organization: Columbia University Medical Center, New York, NY, USA
– sequence: 2
  givenname: Sandra
  surname: Ryeom
  fullname: Ryeom, Sandra
  organization: Columbia University Medical Center, New York, NY, USA
– sequence: 3
  givenname: Bruce L
  surname: Daugherty
  fullname: Daugherty, Bruce L
  organization: Tonix Pharmaceuticals, Inc, Chatham, NJ, USA
– sequence: 4
  givenname: Seth
  surname: Lederman
  fullname: Lederman, Seth
  organization: Columbia University Medical Center, New York, NY, USA
– sequence: 5
  givenname: Timothy C
  surname: Wang
  fullname: Wang, Timothy C
  organization: Columbia University Medical Center, New York, NY, USA
BookMark eNpFkc-O0zAQhyMEEsuyz4AlrmTX_5K4xypLodIWVrRI3KyJ7VQOiV3sZFE57YXH4mV4EpwWxMkzo0-_sf29yJ4670yWvSL4mhBW3nR2VDnFlOXb9a6ei2vMBXmSXVBckJxwWj7PrmLsMMYEMyaEuMh-JeL3488lqr_Unzg6QBgt9Aj23tk4ot1qRfPNdomicdGO9ofRCPQDOJWKPcQxWIXU3AY0enR_mxPU9F59BW1Qc0TxGEczwGgV9P0RBaMnZd0e3W8-5JvbbY1AqWmY-kR49wbZYZicj9PhEEyMpxG4tMg4E04Isg416dlogBD895fZsxb6aK7-npfZ59XbXf0-v_v4bl0v7_KGiIrkUHJdqMbwtlHC0BYzszAtMFCNBmyU5goXGjhoynSjC6MVoaoVuFFYLUTFLrP1OVd76OQh2LT-KD1YeRr4sJfzx6neSM4qZkrBBa8UJy0ReFGlVhdatxrrRcp6fc46BP9tMnGUnZ-CS9eXVAheVrQQOFHsTDVD9x8gWM6q5axazoblP9VyVs3-ABPtpRY
ContentType Journal Article
Copyright Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
2023 Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
– notice: 2023 Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID 9YT
ACMMV
K9.
DOA
DOI 10.1136/jitc-2023-SITC2023.0481
DatabaseName BMJ Open Access Journals
BMJ Journals:Open Access
ProQuest Health & Medical Complete (Alumni)
DOAJ Directory of Open Access Journals
DatabaseTitle ProQuest Health & Medical Complete (Alumni)
DatabaseTitleList ProQuest Health & Medical Complete (Alumni)

Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: ACMMV
  name: BMJ Journals:Open Access
  url: https://journals.bmj.com/
  sourceTypes: Publisher
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2051-1426
EndPage A540
ExternalDocumentID oai_doaj_org_article_4373e684847c41f18097684d5ddfd0d9
jitc
GroupedDBID 4.4
53G
5VS
7X7
88E
8FI
8FJ
9YT
ABUWG
ACGFS
ACMMV
ADBBV
ADRAZ
ADUKV
AFKRA
AHBYD
AHSBF
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AOIJS
ASPBG
AVWKF
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
DIK
EBS
EJD
FYUFA
GROUPED_DOAJ
H13
HMCUK
HYE
IAO
IHR
IHW
INH
INR
ITC
KQ8
M1P
M48
M~E
OK1
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RMJ
ROL
RPM
RSV
SOJ
UKHRP
K9.
PHGZM
PJZUB
PPXIY
PUEGO
ID FETCH-LOGICAL-b1871-a64d5cbe4fbc8e2f03e9efa3acbda0ecd4c05da4ad23dbd5edc12cf80bc0c9873
IEDL.DBID M48
IngestDate Wed Aug 27 01:27:31 EDT 2025
Fri Jul 25 21:17:55 EDT 2025
Thu Apr 24 22:49:44 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue Suppl 1
Language English
License This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-b1871-a64d5cbe4fbc8e2f03e9efa3acbda0ecd4c05da4ad23dbd5edc12cf80bc0c9873
Notes SITC 38th Annual Meeting (SITC 2023) Abstracts
Checkpoint Blockade Therapy
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
OpenAccessLink https://jitc.bmj.com/content/11/Suppl_1/A540.full
PQID 2884672580
PQPubID 2040222
ParticipantIDs doaj_primary_oai_doaj_org_article_4373e684847c41f18097684d5ddfd0d9
proquest_journals_2884672580
bmj_journals_10_1136_jitc_2023_SITC2023_0481
PublicationCentury 2000
PublicationDate 20231100
20231101
2023-11-01
PublicationDateYYYYMMDD 2023-11-01
PublicationDate_xml – month: 11
  year: 2023
  text: 20231100
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
PublicationTitle Journal for immunotherapy of cancer
PublicationTitleAbbrev J Immunother Cancer
PublicationYear 2023
Publisher BMJ Publishing Group Ltd
BMJ Publishing Group LTD
BMJ Publishing Group
Publisher_xml – name: BMJ Publishing Group Ltd
– name: BMJ Publishing Group LTD
– name: BMJ Publishing Group
SSID ssj0001033888
Score 2.2368526
Snippet BackgroundPolymorphonuclear myeloid-derived suppressor cell (PMN-MDSC) is pathologically activated immature neutrophil that exerts immunosuppressive functions....
SourceID doaj
proquest
bmj
SourceType Open Website
Aggregation Database
Publisher
StartPage A540
SubjectTerms Agonists
Bone marrow
Flow cytometry
Gastric cancer
Histamine
Immunotherapy
Lung cancer
Metastasis
Neutrophils
Regular and Young Investigator Award Abstracts
Stem cells
Tumors
SummonAdditionalLinks – databaseName: BMJ Open Access Journals
  dbid: 9YT
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV07b9swECbSFCi6FH2ibtPiho6hTT2oSKOr1EgLKAhqB3Angi8ZTmMpsJUhmbL0Z_XP9Jf0jpbhoVM3iSB4Aj9Sd0fefcfYp8TX-kRYwbWV6KDEPuNFagpurDWy9s5lgcS1Os_OLtNvczk_YNEuF-Zq2dmhWV1t0xmIoKnpRlE0CjUuVTQao4UxpJPpR-wx1SahKK7ix2x_rCLQ58rzPpIrSrIwIqci4Xz6dVbSw5A4UlCXoJieqf-fH3HQLpPn7FlvFsJ4i-MLduCbl-xJ1V98v2K_caw_D7_GUM7L7yncEODYXy9aYr6F2WQS82o6hg3Fo3fLe-9gd7sPC021OSxYel1D18LFKY_AoBr7qZ0Hcwd7Pmd9fX0Ha-JzRZ0GF9U5r06nJWhrb1d9pa9jWFJSSbvBydpG0WKTblBQoLCmLrBswLSNh1XgeHzNLidfZuUZ7ysvcBOhB8V1ljppjU9rY3Mf1yLxBYKaaGucFt661ArpdKpdnDjjpHc2im2dC2OFLfKT5A07bFDKWwY5mQSmtlnhBZpesTZxIrWWmcftWcfJgB0jDqrfORsVnJIkUwSbIrTUDjZFsA3YZwJM3Wy5OBSxY4eGdr1Q_WZTRNfkszxFzWvTqCaKMrpvdNK52glXDNjRDu694DgnUyyWuXj3f5_0nj0NyyskKB6xw2596z-gpdKZj2Ft_gULpOg5
  priority: 102
  providerName: BMJ Publishing Group Ltd
– databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbhMxELZQD4gL4lcECpoDx5p6vT_dPYYtUUFKVZFUys2yx94qpdlEyeZQTlx4LF6GJ2HG2aiVOHDhtmtZO5a_sWdmPf5GiPdpaOyJQiUt5hSg6FDIKnOVdIgub4L3RSRxHZ8XZ5fZl1k-u1fqi3PCdvTAu4k7ZuqdUJQZ7aKYJQ3TTfHZkc-9b7zy8eoe2bx7wVT8u6Io9CrLPqErSYvj63mHkmuFy8nnac0PH5gqhUyKW1z3hP1_7cfRyIyeiMe9dwjD3aieigehfSYejvvz7-fiF33r94-fQ6hn9dcMVjx86m-vlkyAC9PRSMvxZAgbTkvv5t-Dh_0hP1xZLtGBgPy6hm4JF6cyAUfW7Jv1Adwt3NE625ubW1gzrSuZNrgYn8vx6aQGi7hd9AW_jmDOd0uWm-2qT6alJtuSoMhkzV1g3oJbtgEWkerxhbgcfZrWZ7IvwCBdQoGUtAXNM7qQNQ7LoBuVhoqwTS06b1VAn6HKvc2s16l3Pg8eE41NqRwqrMqT9KU4aEnKKwElewauwaIKijwwbZ1Oc2vzItAqbXQ6EEeEg-kX0MbE2CQtDMNmGC2zh80wbAPxkQEzqx0lh2GS7NhAqmN61TH_Up2BONzDfSdYl-yR6bxUr_-HjDfiUVS6eHvxUBx06214S25M595Fjf0DEhDxKw
  priority: 102
  providerName: Directory of Open Access Journals
Title 481 A CXCR4 partial agonist TFF2-MSA sensitized advanced gastric cancer to PD-1 blockade by systematically reducing PMN-MDSC accumulation, immunosuppression, and generation in bone marrow
URI https://jitc.bmj.com/content/11/Suppl_1/A540.full
https://www.proquest.com/docview/2884672580
https://doaj.org/article/4373e684847c41f18097684d5ddfd0d9
Volume 11
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3JbhNBEG2RREJcEKswBKsOHNOhPZtnDlHkTGIFpLGs2EbmNOptLCfe8CJhTlz4LH6GL6Gq05YPoFxm6emeluZVTVX18oqxD6GtZFNowaWOMUAJbMKzSGVcaa3iyhqTOBLXopNcD6LPw3i431nnP-Dqv6Ed5ZMaLCen379tz1Hhz3xGko-347XmlAac9z71c7o4JRaUA3aE5qlJ2lp4n98NvAiMytLUr_V6oD1aGzW99Vz-__yqnf1pP2NPveMIrXukn7NHdvaCPS781PhL9hvf9efnrxbkw_wmggWJBNaXozlx40K_3Q540WvBilasr8c_rIHd_D-MJGXv0KDpdgnrOXQveQMUGro7aSyoLewZn-VksoUlMb6i1YNu0eHFZS8HqfVm6nOBncCYtp3MV5uFX2eLRXKGHTmSa6oC4xmo-czC1LFAvmKD9lU_v-Y-NwNXDYyxuEwiE2tlo0rp1AaVCG2GsIdSKyOF1SbSIjYykiYIjTKxNboR6CoVSgudpc3wNTucYS9vGKTkNKhKJ5kV6JwFUgVhLGWcWFTgKghr7ARxKHeiUbqwJUxKgq0ktModbCXBVmMXBFi5uGfrKIk_2xXMl6PSq2NJhE42SSO0zTpqVERiRjOSJjamMsJkNXa8g3vfcZCSsxbEqXj78ON37IkTJ7dl8Zgdrpcb-x59l7Wqs4PmsInH7Gu_zo5aeVF8wfPFVad7U3fjAXUnrX8BT7H0vg
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV07b9swECbSFGi7BH2ibtL2ho6hTVEPS6Or1HDayAhqBXAngi8ZTmMpsJUhnbr0Z_XP9JeUR8vw0KmbRBA8gR-pu-PxviPkQ2grOWSaUalj56Bwm9AsUhlVWqu4ssYknsS1mCaTq-jzPJ4fkGCXC3O9bHVfra636QxI0FS3gyAY-BqXIhiMnIXRx5PpB-ThEJlXcFF_K_fHKsz5XGna3eQKwsSPSLFIOJ2dlzk-9JEjxekSJ6Zj6v_nR-y1y_gpOerMQhhtcXxGDmz9nDwqusD3C_LbjfXn568R5PP8awS3CLjrLxcNMt9COR5zWsxGsMH76O3yhzWwi-7DQmJtDg0aX9fQNnB5RgNQTo19l8aCuoc9n7O8ubmHNfK5Op0Gl8WUFmezHKTWd6uu0tcpLDGppNm4ydreonVNsnaCPIU1doFlDaqpLaw8x-NLcjX-VOYT2lVeoCpwHhSVSWRirWxUKZ1aXrHQZg7UUGplJLPaRJrFRkbS8NAoE1ujA66rlCnNdJYOw1fksHZSXhNI0SRQlU4yy5zpxaXiYSxlnFi3PSse9sipw0F0O2cjvFMSJgJhE4iW2MEmELYe-YiAidstF4dAdmzf0KwXottsAumabJJGTvPqKKiQogzjjSY2pjLMZD1ysoN7L5inaIrxOGVv_u-T3pPHk7K4EBfn0y_H5Ilfaj5Z8YQctus7-9ZZLa1659fpXx0U6yg
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9NAEF6VIlVcEE8RKDAHjt1k_VjXPoaEqAUSRSSVwmm1L0dpGydK3EM5ceFn8Wf4JcxsHOXAiZttrXYsf7ueb3Z3vmHsQ-JLfS6s4NpKDFBin_EiNQU31hpZeueyIOI6HGUXV-nnmZwdMbnPhble1LZtlte7dAYSaKrqThR1Qo1LFXW6yDDatDLdXrvyAXuI7CUlyfzi-_SwtCIw7srz5jRXlGShV06FwvnkctqjizbppKA_QVONWv8_P-PgYQZP2OOGGkJ3h-VTduSrZ-xk2Gx-P2e_sa8_P391oTfrfUthTaBjez1fkfotTAeDmA8nXdjSmfR68cM72O_ww1xTfQ4Llm43UK9g3OcRGHRlN9p5MPdw0HTWt7f3sCFNV_RrMB6O-LA_6YG29m7ZVPs6gwUllqy2-MF2J2nxka7QUJCxpiawqMCsKg_LoPP4gl0NPk17F7ypvsBNhFEU11nqpDU-LY3NfVyKxBcIbKKtcVp461IrpNOpdnHijJPe2Si2ZS6MFbbIz5OX7LhCK68Y5EQLTGmzwgukX7E2cSK1lpnHKVrGSYudIQ6qmT1bFQKTJFMEmyK01B42RbC12EcCTK13ehyKFLLDg9VmrpoJp0iyyWd5it7XplFJMmW05-ikc6UTrmix0z3cB8NxTnQslrl4_X-v9J6djPsD9fVy9OUNexRGWshXPGXH9ebOv0XiUpt3YZj-BX_17Dc
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=481%E2%80%85A+CXCR4+partial+agonist+TFF2-MSA+sensitized+advanced+gastric+cancer+to+PD-1+blockade+by+systematically+reducing+PMN-MDSC+accumulation%2C+immunosuppression%2C+and+generation+in+bone+marrow&rft.jtitle=Journal+for+immunotherapy+of+cancer&rft.au=Qian%2C+Jin&rft.au=Ryeom%2C+Sandra&rft.au=Daugherty%2C+Bruce+L&rft.au=Lederman%2C+Seth&rft.date=2023-11-01&rft.pub=BMJ+Publishing+Group+LTD&rft.eissn=2051-1426&rft.volume=11&rft.issue=Suppl+1&rft.spage=A540&rft.epage=A540&rft_id=info:doi/10.1136%2Fjitc-2023-SITC2023.0481&rft.externalDBID=HAS_PDF_LINK